Current Status and Future Directions in the Development of Digital Therapeutic Interventions for Neurodevelopmental Disorders

Innovations in digital technologies have emerged digital therapeutics (DTx) as a novel therapeutic intervention. DTx hold potential as novel theragnostics for disorders with broad diagnostic spectra, including neurodevelopmental diseases (NDDs). In this review, they highlight challenging factors in the successful development and deployment of DTx for NDDs with respect to patients, medical professionals, and manufacturers. They also discuss the implications of these factors and future directions for revitalizing DTx development for NDDs.The etiological heterogeneity of neurodevelopmental diseases (NDDs), including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), intellectual disability (ID), and schizophrenia, contributes to variability in clinical phenotypes (i.e., brain structure, intellectual ability, and psychiatric status).